Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05422222
Other study ID # VX21-121-105
Secondary ID 2021-005930-40
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date June 21, 2022
Est. completion date June 2030

Study information

Verified date June 2023
Source Vertex Pharmaceuticals Incorporated
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 210
Est. completion date June 2030
Est. primary completion date June 2030
Accepts healthy volunteers No
Gender All
Age group 1 Year to 11 Years
Eligibility Key Inclusion Criteria: - Participants with stable CF and at least 1 TCR mutation (including F508del) in the CFTR gene Key Exclusion Criteria: - History of solid organ, hematological transplantation, or cancer - Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15) - Lung infection with organisms associated with a more rapid decline in pulmonary status Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
VX-121/TEZ/D-IVA
Fixed-dose combination for oral administration.

Locations

Country Name City State
Australia Telethon Kids Institute Nedlands
Australia Women & Children's Hospital North Adelaide
Australia The Royal Children's Hospital Parkville
Australia Queensland Children's Hospital South Brisbane
France CHU Lyon - Hopital Femme Mere-Enfant Bron Cedex
France Hopital Necker, Enfants Malades Paris Cedex 15
Germany Charite Paediatric Pulmonology Department Berlin
Germany Kinderklinik III, Abt. fur Pneumologie Essen
Germany Medizinische Hochschule Hannover Hannover
Netherlands Erasmus Medical Center / Sophia Children's Hospital Rotterdam
Sweden Sahlgrenska Universitetssjukhuset Göteborg
Switzerland Inselspital - Universitaetsspital Bern Bern
Switzerland Kinderspital Zuerich Zürich
United Kingdom Children and Young Adults Research Unit Cardiff
United Kingdom Great Ormond Street Hospital for Children London
United States The Emory Clinic / Children's Healthcare of Atlanta at Egleston Atlanta Georgia
United States Children's Hospital of Colorado Aurora Colorado
United States Boston Children's Hospital Boston Massachusetts
United States Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center Cleveland Ohio
United States Vermont Lung Center Colchester Vermont
United States Nationwide Children's Hospital Columbus Ohio
United States Texas Children's Hospital - Baylor College of Medicine Houston Texas
United States Riley Hospital for Children at Indiana University Health Indianapolis Indiana
United States The Children's Mercy Hospital Kansas City Missouri
United States University of Wisconsin Hospital and Clinics Madison Wisconsin
United States Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota Minneapolis Minnesota
United States Cohen Children's Medical Center New York New York
United States Children's Hospital of Orange County Orange California
United States Stanford University Palo Alto California
United States UPMC Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States Oregon Health & Science University Portland Oregon
United States Washington University School of Medicine / St. Louis Children's Hospital Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Vertex Pharmaceuticals Incorporated

Countries where clinical trial is conducted

United States,  Australia,  France,  Germany,  Netherlands,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part A: Observed Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ, D-IVA, and Relevant Metabolites From Day 1 up to Day 22
Primary Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Day 1 up to Day 50
Primary Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Day 1 up to Week 28
Secondary Part B: Absolute Change in Sweat Chloride (SwCl) From Baseline Through Week 24
Secondary Part B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ, D-IVA, and Relevant Metabolites From Day 1 up to Week 16
Secondary Part B: Drug Acceptability Assessment Using Modified Facial Hedonic Scale At Day 1 and Week 24
Secondary Part B: Absolute Change in Percent Predicted Forced Expiratory Volume (ppFEV1) From Baseline Through Week 24
Secondary Part B: Number of Pulmonary Exacerbation (PEx) From Baseline Through Week 24
Secondary Part B: Number of CF-Related Hospitalizations From Baseline Through Week 24
Secondary Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score From Baseline Through Week 24
Secondary Part B: Absolute Change in Body Mass Index (BMI) From Baseline at Week 24
Secondary Part B: Absolute Change in BMI-for-age Z-score From Baseline at Week 24
Secondary Part B: Absolute Change in Weight From Baseline at Week 24
Secondary Part B: Absolute Change in Weight-for-age Z-score From Baseline at Week 24
Secondary Part B: Absolute Change in Weight-for-length From Baseline at Week 24
Secondary Part B: Absolute Change in Weight-for-length Z-score From Baseline at Week 24
Secondary Part B: Absolute Change in Height From Baseline at Week 24
Secondary Part B: Absolute Change in Height-for-age Z-score From Baseline at Week 24
Secondary Part B: Absolute Change in Length From Baseline at Week 24
Secondary Part B: Absolute Change in Length-for-age Z-score From Baseline at Week 24
Secondary Part B: Proportion of Participants With SwCl <60 millimole per liter (mmol/L) From Baseline Through Week 24
Secondary Part B: Proportion of Participants With SwCl <30 mmol/L From Baseline Through Week 24
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A